Tectonic Therapeutic Stock Climbs as Broader Market Sinks
Tectonic Therapeutic shares rose 3.6% to $28.42 Wednesday, outpacing biotech benchmarks despite no new company announcements. The firm’s TX45 Phase 2 trial nears full enrollment, with data expected late 2026 or early 2027. Tectonic reported a $25.2 million Q1 loss and has no approved products. Shareholders meet June 8 to vote on directors, auditor, and executive pay.